VOR
VOR clinical trials: Vor Biopharma Inc.
Every trial on ClinicalTrials.gov where Vor Biopharma Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
VOR on the catalyst calendar · VOR registry changes
- Primary completion Dec 2028Sponsor estimatePhase 3NCT07404865Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseVor Biopharma · Primary Sjogren's DiseaseRecruitingVORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 3NCT06456580A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Vor Biopharma · Generalized Myasthenia GravisActive, not recruitingVORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2, 2025ActualPhase 3NCT06456567A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)Vor Biopharma · Systemic Lupus ErythematosusWithdrawnVORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2025ActualPhase 3NCT05306574A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)Vor Biopharma · Systemic Lupus ErythematosusTerminatedVORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2025ActualPhase 1/Phase 2NCT05984199Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell...Vor Biopharma · Leukemia, Myeloid, AcuteTerminatedVORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2025ActualNo phase registeredNCT05309733A Long-term Follow-up Study of Patients Who Received VOR33Vor Biopharma · Leukemia, Myeloid, AcuteTerminatedVORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2025ActualPhase 1/Phase 2NCT04849910Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for...Vor Biopharma · Leukemia, Myeloid, AcuteTerminatedVORLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner